<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000543500"><TermName>anti-mesothelin monoclonal antibody MORAb-009</TermName><TermPronunciation>(AN-tee-MEH-zoh-THEE-lin MAH-noh-KLOH-nul AN-tee-BAH-dee…)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of mesothelioma. Anti-mesothelin monoclonal antibody MORAb-009 binds to a protein called mesothelin, which is found on some cancer cells. Anti-mesothelin monoclonal antibody MORAb-009 may help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called amatuximab and MORAb-009.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718280" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anti-mesothelin monoclonal antibody MORAb-009&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718279" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anticuerpo monoclonal MORAb-009 anti mesotelina&quot;" language="es" id="_4"/><SpanishTermName>anticuerpo monoclonal MORAb-009 anti mesotelina</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del mesotelioma. El anticuerpo monoclonal MORAb-009 anti mesotelina se une a una proteína llamada mesotelina, que se encuentra en algunas células cancerosas. El anticuerpo monoclonal MORAb-009 anti mesotelina podría ayudar al sistema inmunitario a destruir células cancerosas. Es un tipo de anticuerpo monoclonal. También se llama amatuximab y MORAb-009.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-04-13</DateFirstPublished><DateLastModified>2014-03-10</DateLastModified></GlossaryTerm>
